Ovarian Cancer Subtypes May Predict Response to Bevacizumab
Published Online: Monday, June 9, 2014
Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
Most Popular Right Now
Online CME Activities